Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as exenatide twice daily (BID)
exenatide twice daily · 1 trial · 1 indication
Change in HbA1c from baseline after 26 weeks of treatment (i.e., HbA1c at week 26 minus HbA1c at week 0)
Risk for first hypoglycemic episode (blood glucose \<=3.9 mmol/L or severe episode) to occur up to week 26
| Arm | Type | Description |
|---|---|---|
| Exenatide Twice Daily (BID) | EXPERIMENTAL | - |
| Premixed Insulin Aspart Twice Daily (BID) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| exenatide twice daily (BID) | DRUG | subcutaneous injection (5 mcg or 10 mcg), twice a day |
| premixed insulin aspart twice daily (BID) | DRUG | subcutaneous injection (titrated appropriately), twice a day |
Inclusion Criteria: * Have been treated with diet and exercise and a stable, maximally tolerated dose of immediate-release or extended-release metformin, or the combination of metformin (any dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start * Have not received thiazo...
Exenatide twice daily is used to treat Type 2 Diabetes Mellitus. It is a GLP1R agonist developed by AstraZeneca PLC (ticker AZN). The drug is in Phase 3 clinical development and has been studied in a completed Phase 3 trial comparing it with insulin aspart, both added to metformin, in patients with Type 2 Diabetes Mellitus.
Exenatide twice daily targets GLP1R, the glucagon-like peptide-1 receptor, and acts as an agonist at this receptor. By activating GLP1R, the drug is designed to support glycemic control in Type 2 Diabetes Mellitus. It is a small molecule developed by AstraZeneca PLC under ticker AZN.
Exenatide twice daily is developed by AstraZeneca PLC, which trades under the ticker AZN. The company is responsible for the clinical development of this GLP1R agonist for Type 2 Diabetes Mellitus. The asset is currently in Phase 3 development.
Exenatide twice daily is in Phase 3 clinical development for Type 2 Diabetes Mellitus. It is an investigational GLP1R agonist and is not described as approved. One Phase 3 trial has been completed, and no trials are currently active.
Exenatide twice daily has been studied in the completed Phase 3 trial NCT00434954, titled Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes. The trial enrolled 494 participants in Germany, was randomized, active-controlled, and included adults aged 18 years and older.
Yes. Exenatide twice daily is also known as exenatide twice daily (BID). BID stands for twice daily, referring to the dosing frequency. Both names refer to the same GLP1R agonist developed by AstraZeneca PLC (ticker AZN) for Type 2 Diabetes Mellitus.